

SUPPLEMENTARY DATA

***Vitis vinifera* Leaves Extract Liposomal Carbopol Gel Preparation's Potential Wound Healing and Antibacterial Benefits: *In Vivo*, Phytochemical, and Computational Investigation**

5

6 Abeer H. Elmaidomy¹, Soad A. Mohamad², Mahmoud Abdelnaser³, Ramadan Yahia⁴, Fatma A. Mokhtar⁵,
7 Faisal Alsenani⁶, Motaz Y. Badr⁷, Safa Y. Almaghrabi⁸, Faisal H. Altemani⁹, Mubarak A. Alzubaidi¹⁰,
8 Entesar Ali Saber¹¹, Mahmoud A. Elrehany³, Usama Ramadan Abdelmohsen^{12,13}, Ahmed M. Sayed^{14*}

9

10 ¹Department of Pharmacognosy, Faculty of Pharmacy, Beni-Suef University, Beni-Suef 62514, Egypt.
11 Abeer011150@pharm.bsu.edu.eg

12 ²Department of pharmaceuticals and clinical pharmacy, Faculty of Pharmacy, Deraya University, New Minia
13 61111, Egypt

14 ³Department of Biochemistry, Faculty of Pharmacy, Deraya University, New Minia 61111, Egypt

15 ⁴Department of Microbiology and immunology, Faculty of Pharmacy, Deraya University, Universities
16 Zone, New Minia City 1661111, Egypt

17 ⁵Department of Pharmacognosy, Faculty of Pharmacy, ALSalam University, Kafr El Zayat, Egypt

18 ⁶Department of Pharmacognosy, College of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi
19 Arabia; fssenani@uqu.edu.sa; ORCID: 0000-0002-7267-9636.

20 ⁷Department of Pharmaceutics, College of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi
21 Arabia; mybadr@uqu.edu.sa; ORCID: 0000-0003-0737-1894.

22 ⁸Department of Physiology, Faculty of Medicine, King Abdulaziz University, Jeddah 22252, Saudi Arabia;
23 salmaghrabe@kau.edu.sa ORCID: 0000-0001-5713-6732.

24 ⁹Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, University of Tabuk,
25 Tabuk 71491, Saudi Arabia.

26 ¹⁰Department of Biological Sciences, Faculty of Science, King Abdulaziz University, Jeddah 21589, Saudi
27 Arabia.

28 ¹¹Department of Histology and Cell Biology, Faculty of Medicine, Minia University, Minia 61519 Egypt,
29 Delegated to Deraya University, Universities Zone, New Minia 61111, Egypt.

30 ¹²Department of Pharmacognosy, Faculty of Pharmacy, Minia University, Minia 61519, Egypt

31 ¹³Department of Pharmacognosy, Faculty of Pharmacy, Deraya University, New Minia 61111.

32 ¹⁴Department of Pharmacognosy, Faculty of Pharmacy, Nahda University, Beni-Suef 62513, Egypt. 61111,
33 Egypt

34

35 Corresponding author: ahmed.mohamed.sayed@nub.edu.eg

36

37

38

39

40

41

42

43

44

45

46

47

48 **Abstract**

49 *Vitis vinifera* Egyptian edible leaves extract, loaded on Soybean lecithin, cholesterol, and Carbopol
50 gel preparation (VVL-liposomal gel), was prepared to maximize the *in vivo* wound healing, and anti-MRSA
51 activities for the crude extract, using an excision wound model, focusing on TLR-2, MCP-1, CXCL-1, CXCL-
52 2, IL-6 and IL-1 β , and MRSA (wound infection model, and peritonitis infection model). VVL-liposomal gel
53 was stable with significant drug entrapment efficiency reached 88% \pm 3; zeta potential value ranging from -
54 50 to -63, and size from 50-200 μ m nm diameter. The *in vivo* evaluation proved the ability of VVL-liposomal
55 gel to gradually release the drugs in a sustained manner with higher complete wound healing effect and
56 tissue repair after 7 days administration, with significant decrease in bacterial count, comparing with the
57 crude extract. Phytochemical investigation of leaves crude extract yielded fourteen compounds: two new
58 stilbenes (**1**, **2**), with twelve known ones (**3-14**). Furthermore, a computational study was conducted to
59 identify the genes and possible pathways responsible for the anti-MRSA activity of the isolated
60 compounds. Accompanied with inverse docking to identify the most likely molecular targets that could
61 mediate the extract's antibacterial activity. Gyr-B was discovered to be the best target for compounds 1 and
62 2. Hence, VVL-liposomal gel can be used as novel anti-dermatophytic agent with potent wound healing,
63 anti-MRSA capacity, which paving the way for future clinical research.

64

65 **Keywords:** *Vitis vinifera*, MRSA, TLR-2, wound healing, docking, Gyr-B.

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

List of Contents

- Figure S1.** ^1H NMR spectrum of compound **1** measured in CDCl_3-d at 400 MHz
- Figure S2.** DEPT-Q NMR spectrum of compound **1** measured in CDCl_3-d at 100 MHz
- Figure S3.** HSQC spectrum of compound **1** measured in CDCl_3-d
- Figure S4.** HMBC spectrum of compound **1** measured in CDCl_3-d
- Figure S5.** ^1H NMR spectrum of compound **2** measured in CDCl_3-d at 400 MHz
- Figure S6.** DEPT-Q NMR spectrum of compound **2** measured in CDCl_3-d at 100 MHz
- Figure S7.** HSQC spectrum of compound **2** measured in CDCl_3-d
- Figure S8.** HMBC spectrum of compound **2** measured in CDCl_3-d
- Figure S9.** ^1H NMR spectrum of compound **3** measured in $\text{DMSO}-d_6$ at 400 MHz
- Figure S10.** DEPT-Q NMR spectrum of compound **3** measured in $\text{DMSO}-d_6$ at 100 MHz
- Figure S11.** ^1H NMR spectrum of compound **4** measured in $\text{CD}_3\text{OD}-d_4$ at 400 MHz
- Figure S12.** DEPT-Q NMR spectrum of compound **4** measured in $\text{CD}_3\text{OD}-d_4$ at 100 MHz
- Figure S13.** ^1H NMR spectrum of compound **5** measured in $\text{CD}_3\text{OD}-d_4$ at 400 MHz
- Figure S14.** DEPT-Q NMR spectrum of compound **5** measured in $\text{CD}_3\text{OD}-d_4$ at 100 MHz
- Figure S15.** ^1H NMR spectrum of compound **6** measured in $\text{CD}_3\text{OD}-d_4$ at 400 MHz
- Figure S16.** DEPT-Q NMR spectrum of compound **6** measured in $\text{CD}_3\text{OD}-d_4$ at 100 MHz
- Figure S17.** ^1H NMR spectrum of compound **7** measured in $\text{CD}_3\text{OD}-d_4$ at 400 MHz
- Figure S18.** DEPT-Q NMR spectrum of compound **7** measured in $\text{CD}_3\text{OD}-d_4$ at 100 MHz
- Figure S19.** ^1H NMR spectrum of compound **8** measured in $\text{CD}_3\text{OD}-d_4$ at 400 MHz
- Figure S20.** DEPT-Q NMR spectrum of compound **8** measured in $\text{CD}_3\text{OD}-d_4$ at 100 MHz
- Figure S21.** ^1H NMR spectrum of compound **9** measured in $\text{DMSO}-d_6$ at 400 MHz
- Figure S22.** DEPT-Q NMR spectrum of compound **9** measured in $\text{DMSO}-d_6$ at 100 MHz
- Figure S23.** ^1H NMR spectrum of compound **10** measured in CDCl_3-d at 400 MHz
- Figure S24.** DEPT-Q NMR spectrum of compound **10** measured in CDCl_3-d at 100 MHz
- Figure S25.** ^1H NMR spectrum of compound **11** measured in $\text{DMSO}-d_6$ at 400 MHz
- Figure S26.** DEPT-Q NMR spectrum of compound **11** measured in $\text{DMSO}-d_6$ at 100 MHz
- Figure S27.** ^1H NMR spectrum of compound **12** measured in CDCl_3-d at 400 MHz
- Figure S28.** DEPT-Q NMR spectrum of compound **12** measured in CDCl_3-d at 100 MHz
- Figure S29.** ^1H NMR spectrum of compound **13** measured in $\text{CD}_3\text{OD}-d_4$ at 400 MHz
- Figure S30.** DEPT-Q NMR spectrum of compound **13** measured in $\text{CD}_3\text{OD}-d_4$ at 100 MHz
- Figure S31.** ^1H NMR spectrum of compound **14** measured in CDCl_3-d at 400 MHz
- Figure S32.** DEPT-Q NMR spectrum of compound **14** measured in CDCl_3-d at 100 MHz

Oct11-2021-abeer
ABEER-COMP 4
PROTON_BSU CDCl3 (C:\data) abeer 11




Figure S1. 1H NMR spectrum of compound **1** measured in CDCl₃-d at 400 MHz




Figure S2. DEPT-Q NMR spectrum of compound **1** measured in CDCl₃-*d* at 100 MHz




Figure S3. HSQC spectrum of compound **1** measured in CDCl₃-*d*




Figure S4. HMBC spectrum of compound **1** measured in CDCl_3-d




Figure S5. ^1H NMR spectrum of compound **2** measured in $\text{CDCl}_3\text{-}d$ at 400 MHz




Figure S6. DEPT-Q NMR spectrum of compound **2** measured in CDCl_3-d at 100 MHz




Figure S7. HSQC spectrum of compound **2** measured in CDCl_3-d




Figure S8. HMBC spectrum of compound **2** measured in CDCl_3-d




Figure S9. ^1H NMR spectrum of compound **3** measured in $\text{DMSO-}d_6$ at 400 MHz




Figure S10. DEPT-Q NMR spectrum of compound **3** measured in DMSO- d_6 at 100 MHz




Figure S11. ^1H NMR spectrum of compound **4** measured in $\text{CD}_3\text{OD}-d_4$ 400 MHz




Figure S12. DEPT-Q NMR spectrum of compound **4** measured in $\text{CD}_3\text{OD}-d_4$ at 100 MHz




Figure S13. ^1H NMR spectrum of compound **5** measured in $\text{CD}_3\text{OD}-d_4$ at 400 MHz




Figure S14. DEPT-Q NMR spectrum of compound **5** measured in $\text{CD}_3\text{OD}-d_4$ at 100 MHz




Figure S15. ^1H NMR spectrum of compound **6** measured in $\text{CD}_3\text{OD}-d_4$ at 400 MHz




Figure S16. DEPT-Q NMR spectrum of compound 6 measured in $\text{CD}_3\text{OD}-d_4$ at 100 MHz




Figure S17. ^1H NMR spectrum of compound **7** measured in $\text{CD}_3\text{OD}-d_4$ at 400 MHz




Figure S18. DEPT-Q NMR spectrum of compound **7** measured in $\text{CD}_3\text{OD}-d_4$ at 100 MHz

Oct12-2021-abeer
ABEER-COMP 8
PROTON_BSU MeOD {C:\data} abeer 9




Figure S19. ¹H NMR spectrum of compound **8** measured in CD₃OD-*d*₄ at 400 MHz




Figure S20. DEPT-Q NMR spectrum of compound **8** measured in $\text{CD}_3\text{OD}-d_4$ at 100 MHz




Figure S21. ^1H NMR spectrum of compound **9** measured in $\text{DMSO-}d_6$ at 400 MHz




Figure S22. DEPT-Q NMR spectrum of compound **9** measured in DMSO- d_6 at 100 MHz




Figure S23. ^1H NMR spectrum of compound **10** measured in CDCl_3-d at 400 MHz




Figure S24. DEPT-Q NMR spectrum of compound 10 measured in CDCl_3-d at 100 MHz




Figure S25. ¹H NMR spectrum of compound **11** measured in DMSO-*d*₆ at 400 MHz




Figure S26. DEPT-Q NMR spectrum of compound **11** measured in DMSO- d_6 at 100 MHz

Oct13-2021-abeer
ABEER-COMP 7
PROTON_BSU CDCl3 {C:\data\ abeer 24




Figure S27. ^1H NMR spectrum of compound **12** measured in $\text{CDCl}_3\text{-}d$ at 400 MHz




Figure S28. DEPT-Q NMR spectrum of compound **12** measured in CDCl_3-d at 100 MHz

Oct11-2021-abeer
ABEER-COMP 6
PROTON_BSU MeOD {C:\data} abeer 3




Figure S29. ¹H NMR spectrum of compound **13** measured in CD₃OD-*d*₄ at 400 MHz




Figure S30. DEPT-Q NMR spectrum of compound **13** measured in $\text{CD}_3\text{OD}-d_4$ at 100 MHz




Figure S31. ¹H NMR spectrum of compound **14** measured in CDCl₃-d at 400 MHz




Figure S32. DEPT-Q NMR spectrum of compound **14** measured in CDCl_3-d at 100 MHz

Methods

Biological activity predictions using (PASS) software

The neural network-based software Prediction of Activity Spectra for Substances (PASS) [1] (www.way2drug.com) was used for further prioritization of the antimalarial activity of the suggested compounds (1–6). This software can predict > 4000 types of pharmacological and toxicological activities including their mechanism of action, with approximately 85% as acceptable precision, depending on the submitted compound structures that were subsequently screened utilizing the structure–activity relationship database (SARBase). The prediction results were expressed as probability scores (probably active “Pa” or probably inactive “Pi”). These calculated probability scores were determined by linking the structure and functional groups features in the tested molecules that matched or mismatched the specific activities listed in the software-associated database. The higher the Pa values, the more probable the compound to display the suggested pharmacological activity on a scale of 0–1. Pa values higher than 0.5 mean high experimental chance of the suggested pharmacological activity.

Molecular Docking

AutoDock Vina software was used in all molecular docking experiments [2]. All isolated compounds were docked against the Mpro crystal structure (PDB codes: 4PD4) [3]. The binding site was determined according to the enzyme’s co-crystallized ligand. The coordinates of the grid box were: $x = 76.11$; $y = -44.04$; $z = 23.45$. The size of the grid box was set to be 10 Å. Exhaustiveness was set to be 24. Ten poses were generated for each docking experiment. Docking poses were analyzed and visualized using Pymol software [2].

References

- 1- Lagunin, A., Stepanchikova, A., Filimonov, D. & Poroikov, V. PASS: Prediction of activity spectra for biologically active substances. *Bioinformatic*. **16**, 747–748 (2000).
- 2- Seeliger, D.; de Groot, B.L. Ligand docking and binding site analysis with PyMOL and Autodock/Vina. *J. Comput. Aided Mol. Des.* 2010, 24, 417–422.
- 3- Zhang, J., Yang, Q., Romero, J. A. C., Cross, J., Wang, B., Poutsiaka, K. M., ... & Dolle, R. E. (2015). Discovery of indazole derivatives as a novel class of bacterial gyrase B inhibitors. *ACS medicinal chemistry letters*, 6(10), 1080-1085.